---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-070592"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2022-03-09T23:59:59+00:00"
generated_at: "2026-06-27T00:30:02.294601+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics appoints William Ringo as Chair of Board

## Summary
- William Ringo appointed Chair of the Board effective March 8, 2022; also joins compensation and nominating committees.
- Mr. Ringo brings 40+ years of pharma/biotech experience including Pfizer SVP, Eli Lilly executive roles, and CEO of Abgenix.
- Received an option to purchase 29,100 shares and RSU awards totaling 18,933 shares; annual retainers of $79,000.
- Press release announcing appointment issued March 9, 2022.

## SEC filing metadata
- accession: 0001193125-22-070592
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2022-03-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312522070592/0001193125-22-070592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312522070592/d280713d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-070592
- JSON: https://secwatch.observer/filing/0001193125-22-070592.json
- Plain text: https://secwatch.observer/filing/0001193125-22-070592.txt

## Key facts
- Executive change
  William Ringo was appointed as Chair of the Board at Sensei Biotherapeutics, Inc..
  - Action: appointed
  - Role: Chair of the Board
  source text: Effective March 8, 2022, the board of directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) appointed William Ringo to serve as Chair of the Board of the Company and as a member of the Company’s compensation committee and nominating and corporate governance committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312522070592/0001193125-22-070592-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.